Valuation: Scholar Rock Holding Corporation

Market Cap 5.17B 4.64B 4.29B 3.89B 7.26B 493B 7.35B 51.32B 20.44B 258B 19.42B 19.01B 819B P/E 2026 *
-12.9x
P/E 2027 * -16.1x
Enterprise Value 4.86B 4.36B 4.03B 3.65B 6.82B 463B 6.9B 48.18B 19.19B 242B 18.23B 17.85B 769B EV / Sales 2026 *
856x
EV / Sales 2027 * 33.6x
Free-Float
99.27%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Scholar Rock Holding Corporation

1 day+1.79%
1 week+0.58%
Current month-10.49%
1 month-11.97%
3 months-12.40%
6 months-7.45%
Current year-1.82%
1 week 40.76
Extreme 40.76
43.92
1 month 38.69
Extreme 38.69
49.6
Current year 38.69
Extreme 38.69
61.76
1 year 27.07
Extreme 27.07
61.76
3 years 6.76
Extreme 6.76
61.76
5 years 4.32
Extreme 4.325
61.76
10 years 4.32
Extreme 4.325
70
Manager TitleAgeSince
Chief Executive Officer 59 27/04/2025
Director of Finance/CFO 62 27/04/2025
Chief Operating Officer 58 27/04/2025
Director TitleAgeSince
Chairman 59 01/07/2017
Director/Board Member 53 01/08/2014
Director/Board Member 78 01/10/2016
Date Insider Type Main position Quantity % Market Cap. Importance
9/24/26 A Don

Chief Operating Officer

-48,034 0.0394%
9/21/26 A Don

Chief Executive Officer

-36,652 0.0301%
7/1/26 A Sell

Director

-2,544 0.0022%
Change 5-day change 1-year change 3-year change Capi.($)
+1.79%+0.58%+44.75%+275.27% 5.17B
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+2.10%+12.10%+81.21% 54.55B
-0.94%+0.77%+8.85%+100.19% 53.59B
+2.76%+0.87%+27.92%+57.51% 44.75B
+2.00%-3.39%+17.83%+100.08% 41.62B
+1.34%-2.86%+224.43%+928.45% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+48.65%+106.84%+92.73% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.26%-0.10%+51.22%+173.85% 38.56B
Weighted average by Cap. +3.19%-0.25%+47.31%+162.72%

Financials

2026 *2027 *
Net sales 5.67M 5.09M 4.71M 4.26M 7.96M 540M 8.06M 56.28M 22.42M 283M 21.29M 20.84M 898M 142M 127M 118M 106M 199M 13.5B 201M 1.41B 560M 7.06B 532M 521M 22.42B
Net income -427M -383M -354M -321M -599M -40.67B -607M -4.24B -1.69B -21.28B -1.6B -1.57B -67.56B -358M -321M -297M -269M -503M -34.12B -509M -3.55B -1.42B -17.85B -1.34B -1.32B -56.67B
Net Debt -316M -284M -263M -238M -444M -30.14B -450M -3.14B -1.25B -15.77B -1.19B -1.16B -50.07B -410M -368M -340M -308M -576M -39.09B -583M -4.07B -1.62B -20.45B -1.54B -1.51B -64.93B
Projected Income Statement - Annual - Scholar Rock Holding Corporation
Logo Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Employees
289
Date Price Change Volume
28/10/26 $43.25 +1.79% 1,673,012
27/10/26 $42.49 +1.87% 1,161,010
26/10/26 $41.71 +0.53% 1,678,241
23/10/26 $41.49 -1.12% 1,207,039
22/10/26 $41.96 -2.42% 1,133,556
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Scholar Rock Holding Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
42.49USD
Average target price
70.44USD
Spread / Average Target
+65.77%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Scholar Rock Holding Corporation
  1. Stock Market
  2. Stocks
  3. SRRK Stock